SCHEMBL9962610

SCHEMBL9962610

C/C(=N\OC(=O)C(F)(F)F)c1ccc(Sc2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.45
MEN1 O00255 7/20 0.45
KMT2A Q03164 7/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
MAPK1 P28482 3/20 0.45
HTT P42858 3/20 0.45
HPGD P15428 2/20 0.45
ATM Q13315 1/20 0.40
XDH P47989 1/20 0.40
LMNA P02545 2/20 0.40
TSHR P16473 1/20 0.40
GAA P10253 4/20 0.39
ALDH1A1 P00352 4/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
GFER P55789 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CES1 P23141 1/20 0.39
POLB P06746 1/20 0.39
CASP6 P55212 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9962625 0.86 MAPK1 (0.49) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL9962626 0.82 MAPT (0.47) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL13192529 0.82 HPGD (0.40) MAPTMAPK1HPGDLMNATSHR
SCHEMBL267765 0.81 CES1 (0.49) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL12287279 0.77 LMNA (0.43) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL9962630 0.74 RAB9A (0.42) MAPTMEN1KMT2AMAPK1XDH
SCHEMBL16690170 0.73 MAPK1 (0.53) MAPTMEN1KMT2AMAPK1HTT
SCHEMBL9962614 0.72 MAPT (0.46) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL9962608 0.71 SRD5A2 (0.55) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL10022020 0.71 MAPK1 (0.56) MAPTMEN1KMT2ASMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2223910-B1 OXIME ESTERS AND PHOTOPOLYMERIZATION INITIATORS CONTAINING THE SAME ADEKA CORP (JP) 2012-11-07 EP disclosed
US-8202679-B2 Oxime ester compound and photopolymerization initiator containing the same ADEKA CORPORATION (JP) 2012-06-19 US disclosed
US-8202679-B2 Oxime ester compound and photopolymerization initiator containing the same ADEKA CORPORATION (JP) 2012-06-19 US disclosed
US-20100249262-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME ADEKA CORPORATION (JP) 2010-09-30 US disclosed
US-20100249262-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME ADEKA CORPORATION (JP) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249262-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME OXER1, CYP4A11, NR2E3 MAPT 4574/4885MEN1 4343/4885KMT2A 3908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.